Loading...
XKRX
206640
Market cap201mUSD
Dec 05, Last price  
13,530.00KRW
1D
0.89%
1Q
-5.58%
Jan 2017
-27.93%
IPO
-32.35%
Name

Boditech Med Inc

Chart & Performance

D1W1MN
XKRX:206640 chart
P/E
10.90
P/S
2.15
EPS
1,240.93
Div Yield, %
1.48%
Shrs. gr., 5y
-0.93%
Rev. gr., 5y
13.67%
Revenues
138.16b
+2.94%
39,821,415,29854,974,499,12052,593,956,50066,204,377,38072,798,657,278144,131,041,846157,707,960,354118,076,842,537134,219,239,677138,160,173,000
Net income
27.26b
+5.06%
-1,970,266,06412,620,723,299-2,147,728,007-1,690,693,84411,649,991,87045,489,250,57044,366,589,21024,151,534,40025,946,635,99027,260,388,000
CFO
24.88b
-27.47%
9,632,299,67611,790,575,204886,736,1475,314,864,01917,242,231,86544,642,882,66949,927,140,40723,068,407,64434,299,696,34024,878,655,000
Dividend
Mar 29, 2024200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician's clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle. Its solutions cover areas, such as cardiac, cancer, diabetes, hormone, infection, infectious disease, gastrointestinal, rheumatoid arthritis, and others. The company offers its products through a network of approximately 100 sales agencies worldwide. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon, South Korea.
IPO date
Dec 29, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT